Post-translational modifications (PTM) by members of the Ubiquitin (Ub) family represent an efficient way to regulate almost every biological process. Defects in this homeostatic equilibrium, result in pathologies such as cancer, neurodegeneration, inflammation or multiple infections. For this reason, this research area has become very attractive for fundamental scientists as well as for the pharmaceutical industry aiming to identify potential targets for therapeutic intervention.

UbiCODE is a scientific consortium funded by the European Union, bringing together 11 research institutions across 5 European countries to decipher the ubiquitin code and train 13 PhD students in this field.